Phase II
This morning, Merck hosted a cardiovascular investment event where it touted the advances it’s made in its pipeline, which includes a portfolio that has tripled in size over the past year.
Discover what’s in store for today’s presentations at The American Academy of Neurology’s annual meeting, which will include data for a variety of neurological treatments.
Imara stock plunged 40% after announcing the failure of Phase II sickle cell and beta-thalassemia trials and plans to discontinue development.
The company’s shares rose by 29.6% on NASDAQ shortly after the announcement.
Alcohol use disorder is common among the population for a very long time. Adial is planning to leverage genomics that can treat pervasive alcohol use disorder.
The 2022 American Academy of Neurology (AAN) Annual Meeting kicked off on Saturday and will continue on through Thursday.
Three studies supporting Merck and Ridgeback Biotherapeutics’ Lagevrio (molnupiravir) will be presented at the ECCMID 2022 in Lisbon from April 23-26.
The 71st annual American College of Cardiology’s Scientific Session saw several wins over the weekend, led by some of the life sciences industries’ largest companies.
It was a particularly busy week for clinical trial announcements. Let’s take a look.
The FDA requested additional data analyses from the pediatric studies that Merck stated it has submitted. The final decision is expected on July 1, 2022.
PRESS RELEASES